A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection
Authors:
- Daniela P. LageDLDaniela P. Lage
- Danniele L. ValeDVDanniele L. Vale
- Flávia P. LinharesFLFlávia P. Linhares
- Camila S. FreitasCFCamila S. Freitas
- Amanda S. MachadoAMAmanda S. Machado
- Jamille M. O. CardosoJCJamille M. O. Cardoso
- Daysiane de OliveiraDODaysiane de Oliveira
- Nathália C. GalvaniNGNathália C. Galvani
- Marcelo P. de OliveiraMOMarcelo P. de Oliveira
- João A. Oliveira-Da-SilvaJOJoão A. Oliveira-Da-Silva
- Fernanda F. RamosFRFernanda F. Ramos
- Grasiele S. V. TavaresGTGrasiele S. V. Tavares
Open Access
Abstract
Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL), a potentially fatal disease caused by infection with Leishmania parasites. In the current study, a recombinant chimeric protein ChimT was developed based on T-cell epitopes identified from the immunogenic Leishmania amastigote proteins LiHyp1, LiHyV, LiHyC and LiHyG. ChimT was associated with the adjuvants saponin (Sap) or monophosphoryl lipid A (MPLA) and used to immunize mice, and their immunogenicity and protective efficacy were evaluated. Both ChimT/Sap and ChimT/MPLA induced the development of a specific Th1-type immune response, with significantly high levels of IFN-γ, IL-2, IL-12, TNF-α and GM-CSF cytokines produced by CD4+ and CD8+ T cell subtypes (p < 0.05), with correspondingly low production of anti-leishmanial IL-4 and IL-10 cytokines. Significantly increased (p < 0.05) levels of nitrite, a proxy for nitric oxide, and IFN-γ expression (p < 0.05) were detected in stimulated spleen cell cultures from immunized and infected mice, as was significant production of parasite-specific IgG2a isotype antibodies. Significant reductions in the parasite load in the internal organs of the immunized and infected mice (p < 0.05) were quantified with a limiting dilution technique and quantitative PCR and correlated with the immunological findings. ChimT/MPLA showed marginally superior immunogenicity than ChimT/Sap, and although this was not statistically significant (p > 0.05), ChimT/MPLA was preferred since ChimT/Sap induced transient edema in the inoculation site. ChimT also induced high IFN-γ and low IL-10 levels from human PBMCs isolated from healthy individuals and from VL-treated patients. In conclusion, the experimental T-cell multi-epitope amastigote stage Leishmania vaccine administered with adjuvants appears to be a promising vaccine candidate to protect against VL.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ-02167-21, APQ-408675/2018-7, MR/R005850/1)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (APQ-02167-21, APQ-408675/2018-7, MR/R005850/1)
- Medical Research Council (APQ-02167-21, APQ-408675/2018-7, MR/R005850/1)
This publication has 64 references indexed in Scilit:
- A Review of Preventative Methods against Human Leishmaniasis InfectionPLOS Neglected Tropical Diseases, 2013
- A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasisInternational Journal for Parasitology, 2012
- Leishmaniasis: complexity at the host–pathogen interfaceNature Reviews Microbiology, 2011
- Evaluation of Ex Vivo Human Immune Response against Candidate Antigens for a Visceral Leishmaniasis VaccineThe American Journal of Tropical Medicine and Hygiene, 2010
- Ubiquitin Conjugation of Open Reading Frame F DNA Vaccine Leads to Enhanced Cell-Mediated Immune Response and Induces Protection against Both Antimony-Susceptible and -Resistant Strains of Leishmania donovaniThe Journal of Immunology, 2009
- Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvantsVaccine, 2009
- Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasisVaccine, 2008
- Interleukin-10 and the pathogenesis of human visceral leishmaniasisTrends in Immunology, 2007
- Immunohistological features of visceral leishmaniasis in BALB/c miceParasite Immunology, 2006
- Immune Responses Induced by theLeishmania(Leishmania)donovaniA2 Antigen, but Not by the LACK Antigen, Are Protective against ExperimentalLeishmania(Leishmania)amazonensisInfectionInfection and Immunity, 2003